Where do you start when developing a new medicine?
27 March 2014 | By GlaxoSmithKline
Novel scientific collaboration to use genomics and big data to drive drug discovery...
List view / Grid view
News
Merck announces appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, who has served in the role since 2007
27 March 2014 | By Merck
Merck announced the appointment of Robert M. Davis as executive vice president and chief financial officer, effective April 23, 2014....
In a subanalysis, the benefits of eliquis® (apixaban) vs. Warfarin in reducing the risk of stroke in patients with nonvalvular atrial fibrillation were consistent, regardless of blood pressure control
27 March 2014 | By Bristol-Myers Squibb
Blood pressure control key factor in stroke risk...
TESCAN ORSAY HOLDING, a.s. and WITec GmbH launch the RISE Microscope for correlative Raman-SEM Imaging at Analytica 2014
27 March 2014 | By WITec
TESCAN ORSAY HOLDING, a.s. and WITec GmbH jointly launch RISE Microscopy at Analytica 2014...
EMA reorganisation: changes to handling of certain evaluation procedures to be introduced from 1 April 2014
26 March 2014 | By The European Medicines Agency
Handling of all other evaluation procedures to remain unchanged until further announcement later this year...
Pfizer achieves primary endpoint with Phase 3b top-line results of GENOTROPIN® in very young children born small for gestational age
26 March 2014 | By Pfizer
Pfizer Inc. announced the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN®...
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan®
26 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide)...
AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K.
26 March 2014 | By AstraZeneca
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K...
New Asia Tube Cooler from Syrris enables extra low temperature flow reactions
26 March 2014 | By kdm communications
Syrris is pleased to announce the launch of the Asia Tube Cooler, the latest addition to the Company’s range of advanced flow chemistry products...
Cancer Research UK launches trial to fight cancer caused by a common virus
26 March 2014 | By Cancer Research UK
Cancer Research UK’s Drug Development Office has launched a trial of a vaccine to treat some forms of cancer caused by a common virus known as the Epstein Barr Virus...
Eliminate tedious sample preparation with laboratory automation from Tecan
25 March 2014 | By kdm communications
Tecan offers a wide range of laboratory automation solutions for mass spectrometry sample preparation, ensuring there is a system to meet your workflow and throughput needs...
Daiichi Sankyo to facilitate new Drug Discovery in 2014 through Collaborative Research and Grants
25 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2014...
Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies...
Daiichi Sankyo receives approval in Japan for manufacturing and marketing of the antiplatelet agent Efient® 3.75mg/5mg tablets
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for the antiplatelet agent Efient® 3.75mg/5mg Tablets...
Abbvie to present detailed results from phase iii studies in patients with chronic hepatitis C at the 2014 International Liver Congress™
24 March 2014 | By AbbVie
AbbVie will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™...
